In a $6B deal, Cambridge biotech sells experimental psoriasis drug to Takeda
In one of the largest acquisitions of a drug this year, Takeda has agreed to buy a drug in mid-stage development for autoimmune diseases for $4 billion upfront plus $2 billion in milestone payments from Cambridge-based Nimbus Therapeutics.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
More News: Autoimmune Disease | Biotechnology | Health Management | Mergers and Aquisitions | Pharmaceuticals | Psoriasis